Sun Pharmaceuticals Industries Ltd (SUNPHARMA)
₹1619.45▲1.11%
Analyst Rating
based on 36 analysts
63.89%
Buy
27.78%
Hold
8.33%
Sell
Based on 36 analysts offering long term price targets for Sun Pharmaceuticals Industries Ltd. An average target of ₹1629.14
Source: S&P Global Market Intelligence
Sun Pharmaceuticals Industries Ltd Share analysis
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹1,592₹1,624.9552 Week's Low
52 Week's High
₹1,068.35₹1,638.85
| Returns % | |
| 1 Month Return | + 7.17 % |
| 3 Month Return | + 7.8 % |
| 1 Year Return | + 45.55 % |
| Market Stats | |
| Previous Close | ₹1,601.60 |
| Open | ₹1,602.00 |
| Volume | 29.23L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹3,84,277.49Cr |
Key Statistics
| P/E Ratio | 40.14 |
| PEG Ratio | 8.73 |
| Market Cap | ₹3,84,277.49 Cr |
| P/B Ratio | 16.41 |
| EPS | 17.45 |
Peer Comparison
Mutual Fund Holdings
Company Information
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Share Price: ₹1619.45 per share as on 24 Jul, 2024 04:01 PM
Market Capitalisation: ₹3,84,277.49Cr as of today
Revenue: ₹11,813.33Cr as on March 2024 (Q1 24)
Net Profit: ₹2,666.59Cr as on March 2024 (Q1 24)
Listing date: 09 Feb, 1995
| Organisation | Sun Pharmaceuticals Industries Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Sun Pharmaceuticals Industries Ltd
Sun Pharma Stock Up 1.15% on NSE - 24 Jul, 2024
Sun Pharmaceuticals Industries Ltd stock is up 1.15% on the NSE, gaining around 7.63% in the last month and 47.94% in the last year. The PE of the stock is 125.97 based on TTM earnings ending March 24.
Sun Pharma Loses Plea Against NPPA Demand Notice - 18 Jul, 2024
The Supreme Court has dismissed Sun Pharma's plea against a demand notice of Rs 4.65 crore raised by the National Pharmaceutical Pricing Authority (NPPA) for overcharging on Roscilox drug. Additionally, Sun Pharma and other major drugmakers are increasing their R&D expenditure to focus on specialised drugs, but require government support.
USFDA Warning Letter Causes Sun Pharma Stock to Drop - 16 Jul, 2024
Sun Pharmaceuticals Industries Ltd received a warning letter from the US Food and Drug Administration (USFDA) regarding inadequate cleanliness and maintenance of equipment at its Dadra manufacturing plant. This caused a 2% drop in the company's stock.
Sun Pharma Faces Legal Setback; Sharekhan Recommends Buying Stock - 15 Jul, 2024
Sun Pharmaceuticals faces a legal setback as the Supreme Court upholds NPPA's decision to recover Rs 4.65 crore towards excess pricing. However, Sharekhan recommends buying the stock with a target of Rs 1,800, implying returns of up to 14%.
Sun Pharma Expects High Growth in FY25 with Increased R&D Spending - 09 Jul, 2024
Sun Pharmaceuticals Industries Ltd is expecting high single-digit consolidated topline growth for FY25 and plans to increase R&D spending to 8-10% of its revenues. The company also plans to commence patient enrollment for phase-2 trials of its weight loss drug, GLP-1R.
Sun Pharma Open to Acquisitions in Global Specialty Portfolio - 08 Jul, 2024
Sun Pharmaceuticals Industries Ltd ended FY24 with a strong net cash position of $2.4bn and is considering inorganic opportunities in the global specialty portfolio. The contribution of global specialty increased from 7% to 18% of consolidated revenues between FY19 and FY24.
Sun Pharma Declares Final Dividend and Shows Positive Momentum - 06 Jul, 2024
Sun Pharmaceuticals Industries Ltd has declared a final dividend of Rs. 5 per equity share and its stock has gained for two consecutive weeks, indicating positive momentum and an expected appreciation to ₹1,800 over the medium term.
Mixed News for Sun Pharma Stock - 05 Jul, 2024
Sun Pharma is facing recalls due to manufacturing issues but has positive news regarding its specialty drug and upcoming product launches. ICICI Securities recommends a bull call spread for the stock.
Sun Pharma Faces Warning Letter and Recall; Reports Strong Q4 Results - 04 Jul, 2024
Sun Pharmaceuticals Industries Ltd faces a warning letter from the USFDA for significant violations of Current Good Manufacturing Practice (CGMP) regulations at its Dadra plant. The company's US-based unit also recalled Decitabine for Injection due to CGMP deviations. However, the pharma major reported strong Q4 results with a 33.77% jump in consolidated net profit. Additionally, the European Medicines Agency validated the submission of the marketing authorization application for Nidlegy.
Sun Pharma Shares Fall After Warning Letter from USFDA - 03 Jul, 2024
Sun Pharma's shares fell 1.68% after the USFDA issued a warning letter to its Dadra unit for serious compliance issues, including repeat violations and inadequate oversight. The regulator recommended that Sun Pharma engage a consultant to meet current good manufacturing practices requirements.
Sun Pharma Launches #SecondBirthDate 2.0 Campaign - 01 Jul, 2024
Sun Pharma launched its #SecondBirthDate 2.0 campaign on National Doctors Day, featuring Bollywood actor Sushmita Sen to express gratitude to doctors. Additionally, Sun Pharma remains the top bet in the pharma space due to its convincing risk versus reward and valuation.
Sun Pharma Shows Impressive Annual EPS Growth - 30 Jun, 2024
Sun Pharmaceutical Industries has shown an impressive annual EPS growth of 49% over the last three years, with sustainable revenue growth of 11%. Insiders own a significant stake in the company, and good governance is suggested by the CEO's compensation package being below the median for similarly sized companies.
Sun Pharma Acquires Stakes in Healthcare Startups - 27 Jun, 2024
Sun Pharmaceutical Industries Ltd has acquired stakes in digital healthcare startups Agatsa Software, Remidio Innovative Solutions and EzeRx. The acquisition of these stakes is part of Sun Pharma's strategy to expand its presence in the healthcare sector.
Sun Pharma Invests in Weight-Loss Drugs Research - 26 Jun, 2024
Sun Pharma's Dilip Shanghvi is betting on weight-loss drugs and plans to further research a new drug candidate after an encouraging early clinical trial. However, experts caution that success may take several years and the competitive landscape is rapidly changing.
Sun Pharma Completes Merger with Taro Pharmaceuticals - 25 Jun, 2024
Sun Pharma has successfully completed the $347.73 million merger with Taro Pharmaceutical Industries, acquiring all outstanding shares to become a wholly-owned subsidiary. Elara Securities maintains an optimistic outlook on Sun Pharma's potential for growth in both existing and new products.
Insights on Sun Pharmaceuticals Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 3 Years
In the last 3 years, SUNPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 12.21% to 12.78% in Jun 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 8.97% to 9.01% in Jun 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 5 quarters, 1.98K Cr → 2.65K Cr (in ₹), with an average increase of 6.9% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, SUNPHARMA stock has moved up by 0.5%
NO EFFECTAgainst Peers
In the last 1 year, Zydus Lifesciences Ltd has given 87.2% return, outperforming this stock by 41.6%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Jun 2024 quarter
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 12.63K Cr → 12.58K Cr (in ₹), with an average decrease of 0.3% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 17.72% to 17.23% in Jun 2024 quarter
News
Sun Pharmaceutical Industries Stocks Live Updates: Sun Pharma Closes at Rs 1568.65 with 0.51% Weekly Return
Welcome to the Sun Pharmaceutical Industries Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ahead of the... Read more
23 Jul, 2024 08:33 AMCash Market | Sun Pharma breaks out of the falling channel
RSI has given a trendline breakout and MACD has given a bullish crossover in Sun Pharma
24 Jul, 2024 07:10 AMSun Pharmaceuticals Industries Ltd rises for third straight session
Sun Pharmaceuticals Industries Ltd is quoting at Rs 1620, up 1.15% on the day as on 12:49 IST on the NSE. The stock is up 47.94% in last one year as compared to... Read more
24 Jul, 2024 01:05 PMCompany Financials
| Q'1 24 | Q/Q Change | |
|---|---|---|
Revenue | ₹11,813.33Cr | ↓2.83% |
Net Income | ₹2,666.59Cr | ↑3.84% |
Net Profit Margin | 22.57% | ↑6.87% |
| 2024 | Y/Y Change | |
|---|---|---|
Revenue | ₹48,496.85Cr | ↑10.51% |
Net Income | ₹9,648.44Cr | ↑12.70% |
Net Profit Margin | 19.89% | ↑1.95% |
| 2024 | Y/Y Change | |
|---|---|---|
Total Assets | ₹41,896.83Cr | ↓0.10% |
Total Liabilities | ₹18,202.43Cr | ↑0.07% |
| 2024 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -₹292.42Cr | ↓157.67% |
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 17.23% | ||
| Mutual Funds | 12.78% | 4.67 | |
| Retail Investors | 9.01% | 0.45 | |
| Others | 6.5% |
Key Indicators
Sun Pharmaceuticals Industries Ltd Valuation
Sun Pharmaceuticals Industries Ltd in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (40.14x)
July 23, 2024
Industry (56.07x)
July 23, 2024
Highest (184.63x)
August 28, 2020
Earnings and Dividends
Sun Pharmaceuticals Industries Ltd Earnings Results
Sun Pharmaceuticals Industries Ltd’s net profit jumped 33.77% since last year same period to ₹2,654.58Cr in the Q4 2023-2024. On a quarterly growth basis, Sun Pharmaceuticals Industries Ltd has generated 5.18% jump in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceuticals Industries Ltd Dividends May,2024
In the quarter ending March 2024, Sun Pharmaceuticals Industries Ltd has declared dividend of ₹5 - translating a dividend yield of 1.09%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Sun Pharmaceuticals Industries Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Sun Pharmaceuticals Industries Ltd shares.
Sun Pharmaceuticals Industries Ltd (SUNPHARMA) share price today is ₹1619.45
Sun Pharmaceuticals Industries Ltd is listed on NSE
Sun Pharmaceuticals Industries Ltd is listed on BSE
- Today’s highest price of Sun Pharmaceuticals Industries Ltd is ₹1624.95.
- Today’s lowest price of Sun Pharmaceuticals Industries Ltd is ₹1592.
PE Ratio of Sun Pharmaceuticals Industries Ltd is 40.14
PE ratio = Sun Pharmaceuticals Industries Ltd Market price per share / Sun Pharmaceuticals Industries Ltd Earnings per share
Today’s traded volume of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is 29.23L.
Today’s market capitalisation of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is ₹384277.49Cr.
| Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Price |
|---|---|
52 Week High | ₹1638.85 |
52 Week Low | ₹1068.35 |
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1619.45. It is down -1.18% from its 52 Week High price of ₹1638.85
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1619.45. It is up 51.58% from its 52 Week Low price of ₹1068.35
| Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Returns |
|---|---|
1 Day Returns | 17.85% |
1 Month Returns | 7.17% |
3 Month Returns | 7.8% |
1 Year Returns | 45.55% |